Home Stock

Stock Research: Royalty Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Royalty Pharma

NSQ:RPRX GB00BMVP7Y09
98
  • Value
    96
  • Growth
    20
  • Safety
    Safety
    85
  • Combined
    89
  • Sentiment
    96
  • 360° View
    360° View
    98
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry. The company operates across the biopharmaceutical industry, collaborating with various innovators from academic institutions to global pharmaceutical companies, and has a portfolio including royalties on over 35 commercial products like Vertex’s Trikafta and GSK’s Trelegy. In the last fiscal year, the company had a market cap of $20527 million, profits of NULL, revenue of $2264 million, and 99 employees.

more
Strongest Rank Leverage
Weakest Rank 360° View
Country USA
Industry Pharmaceuticals
Size Medium
Website royaltypharma.com
Index
NASDAQ
D.J. US Health Care
D.J. US Pharmaceutical
Royalty Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 96 96 83
Growth
20 59 15 23
Safety
Safety
85 45 52 58
Sentiment
96 94 63 43
360° View
360° View
98 96 72 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
45 75 77 40
Opinions Change
88 89 29 72
Pro Holdings
n/a 96 55 36
Market Pulse
40 23 45 46
Sentiment
96 94 63 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 96 96 83
Growth
20 59 15 23
Safety Safety
85 45 52 58
Combined
89 88 59 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
67 11 14 12
Price vs. Earnings (P/E)
20 93 95 75
Price vs. Book (P/B)
64 65 60 50
Dividend Yield
97 94 94 92
Value
96 96 96 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
38 45 11 19
Profit Growth
54 37 51 57
Capital Growth
19 79 49 43
Stock Returns
42 57 33 51
Growth
20 59 15 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
14 40 44 46
Refinancing
98 14 35 27
Liquidity
77 75 75 82
Safety Safety
85 45 52 58

Similar Stocks

Discover high‑ranked alternatives to Royalty Pharma and broaden your portfolio horizons.

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Omnicom

NYQ:OMC
Country: USA
Industry: Advertising
Size: X-Large
Full Stock Analysis

Mosaic

NYQ:MOS
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Labcorp

NYQ:LH
Country: USA
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews